Literature DB >> 15661022

Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects.

Anne Durandy1, Patrick Revy, Kohsuke Imai, Alain Fischer.   

Abstract

Hyper-immunoglobulin M (IgM) syndromes are primary immunodeficiencies characterized by normal or elevated serum IgM levels with the absence of other isotypes, pinpointing to a defect in the Ig class switch recombination (CSR). The delineation of hyper-IgM syndromes made it possible to better define the mechanisms underlying the two major events of antibody maturation in humans, CSR and introduction of somatic hypermutation (SHM) in the variable region of immunoglobulins. The description of the activation-induced cytidine deaminase (AID) deficiency, characterized by a defect in both CSR and SHM, demonstrated for the first time that this molecule acts as a master player in the antigen-induced Ig gene-modification events responsible for both CSR and SHM. However, deleterious mutations located in the C-terminus lead to a CSR defect without affecting SHM, providing evidence for a role of AID in CSR distinct from the cytidine deaminase activity, likely by binding to a specific CSR cofactor. Molecular causes of two other hyper-IgM conditions have not yet been defined. However, they may be caused by either a defect in AID targeting on S regions or a CSR-specific DNA-repair defect. The mechanism of action of AID remains somewhat debated, but the observation that uracil-DNA-glycosylase deficiency leads to a severe hyper-IgM syndrome strongly argues in favor of a DNA-editing activity of AID.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661022     DOI: 10.1111/j.0105-2896.2005.00222.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  23 in total

Review 1.  Clinical consequences of defects in B-cell development.

Authors:  Andre M Vale; Harry W Schroeder
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

2.  Immunodeficiencies due to defects of class-switch recombination.

Authors:  Luigi D Notarangelo; Gaetana Lanzi; Paola Toniati; Silvia Giliani
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 3.  Study of patients with Hyper-IgM type IV phenotype who recovered spontaneously during late childhood and review of the literature.

Authors:  Neslihan Edeer Karaca; Anne Durandy; Nesrin Gulez; Guzide Aksu; Necil Kutukculer
Journal:  Eur J Pediatr       Date:  2011-01-28       Impact factor: 3.183

Review 4.  Selective IgM Deficiency: Clinical and Laboratory Features of 17 Patients and a Review of the Literature.

Authors:  Zita Chovancova; Pavlina Kralickova; Alena Pejchalova; Marketa Bloomfield; Jana Nechvatalova; Marcela Vlkova; Jiri Litzman
Journal:  J Clin Immunol       Date:  2017-07-21       Impact factor: 8.317

Review 5.  Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome.

Authors:  Xiangxue Meng; Bin Yang; Wen-Chen Suen
Journal:  Innate Immun       Date:  2017-11-13       Impact factor: 2.680

6.  Activation-induced cytidine deaminase mediates central tolerance in B cells.

Authors:  Masayuki Kuraoka; T Matt Holl; Dongmei Liao; Mandy Womble; Derek W Cain; Alexander E Reynolds; Garnett Kelsoe
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-23       Impact factor: 11.205

7.  Activation-induced cytidine deaminase deficiency accelerates autoimmune diabetes in NOD mice.

Authors:  Qiyuan Tan; Ningwen Tai; Yangyang Li; James Pearson; Sean Pennetti; Zhiguang Zhou; F Susan Wong; Li Wen
Journal:  JCI Insight       Date:  2018-01-11

8.  Late stages of hematopoiesis and B cell lymphopoiesis are regulated by α-synuclein, a key player in Parkinson's disease.

Authors:  Wenbin Xiao; Afshin Shameli; Clifford V Harding; Howard J Meyerson; Robert W Maitta
Journal:  Immunobiology       Date:  2014-07-22       Impact factor: 3.144

Review 9.  A coming-of-age story: activation-induced cytidine deaminase turns 10.

Authors:  Rebecca K Delker; Sebastian D Fugmann; F Nina Papavasiliou
Journal:  Nat Immunol       Date:  2009-10-20       Impact factor: 25.606

Review 10.  Understanding systemic lupus erythematosus physiopathology in the light of primary immunodeficiencies.

Authors:  Magda Carneiro-Sampaio; Bernadete Lourdes Liphaus; Adriana Almeida Jesus; Clovis Artur A Silva; João Bosco Oliveira; Maria Helena Kiss
Journal:  J Clin Immunol       Date:  2008-04-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.